Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.61 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.61 |
| ▸ | ACE | P12821 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.53 |
| ▸ | CTSS | P25774 | 6/20 | 0.52 |
| ▸ | CTSK | P43235 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | KDM4A | O75164 | 1/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.51 |
| ▸ | BCL2 | P10415 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 4/20 | 0.49 |
| ▸ | PPARG | P37231 | 3/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.48 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1932580 | 1.00 | ITGB3 (0.61) | ITGB3ITGA2BACEPTPN1CTSS | |
| SCHEMBL2853779 | 1.00 | ITGB3 (0.61) | ITGB3ITGA2BACEPTPN1CTSS | |
| SCHEMBL2856826 | 0.92 | ITGB3 (0.52) | ITGB3ITGA2BACEPTPN1CTSS | |
| SCHEMBL18235378 | 0.92 | ITGB3 (0.52) | ITGB3ITGA2BACEPTPN1CTSS | |
| SCHEMBL2856829 | 0.92 | ITGB3 (0.52) | ITGB3ITGA2BACEPTPN1CTSS | |
| SCHEMBL7442384 | 0.91 | KLK5 (0.53) | ITGB3ITGA2BACEPTPN1CTSS | |
| SCHEMBL864694 | 0.91 | KLK5 (0.53) | ITGB3ITGA2BACEPTPN1CTSS | |
| SCHEMBL1819934 | 0.91 | KLK5 (0.53) | ITGB3ITGA2BACEPTPN1CTSS | |
| SCHEMBL28706872 | 0.91 | REN (0.52) | ITGB3ITGA2BACEPTPN1CTSS | |
| SCHEMBL31448103 | 0.91 | ITGB3 (0.61) | ITGB3ITGA2BACEPTPN1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807669-B2 | Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-10-05 | — | — | US | disclosed |
| EP-1575911-B1 | BIAROMATIC COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2010-01-13 | — | — | EP | disclosed |
| US-20090062340-A1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-03-05 | — | — | US | disclosed |
| US-7452878-B2 | Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-11-18 | — | — | US | disclosed |
| US-20050256116-A1 | Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-11-17 | — | — | US | disclosed |
| US-5354892-A | Treating cardiovascular disorders; endopeptidase inhibitors; diuretics | CIBA-GEIGY CORPORATION (US) | 1994-10-11 | — | — | US | disclosed |
| EP-0555175-A1 | Biaryl substituted 4-amino-butyric acid amides | CIBA-GEIGY AG (CH) | 1993-08-11 | — | — | EP | disclosed |
| US-5217996-A | Endopeptidase inhibitors | CIBA-GEIGY CORPORATION (US) | 1993-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062340-A1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF | PPARG, PPARA, PPARD | ITGB3 4287/4885ITGA2B 3296/4885ACE 2858/4885 |
| US-20050256116-A1 | Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | ITGB3 4287/4885ITGA2B 3296/4885ACE 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.